{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:12Z","timestamp":1792036812795,"version":"4.4.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82394450"],"award-info":[{"award-number":["82394450"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92459301"],"award-info":[{"award-number":["92459301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["23XD1400800"],"award-info":[{"award-number":["23XD1400800"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fund of Fudan University and Cao'ejiang Basic Research","award":["24FCB09"],"award-info":[{"award-number":["24FCB09"]}]},{"name":"Fund of Fudan University","award":["FudanX24AI043"],"award-info":[{"award-number":["FudanX24AI043"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As one of the most promising classes of next-generation antibody therapeutics, bispecific antibodies (bsAbs) have gained increasing attention owing to their unique dual-targeting mechanisms. However, current bsAb formats often face challenges such as low expression levels, poor homogeneity, and unstable therapeutic efficacy due to their complex structures. Therefore, it is urgent to overcome the current technical limitations and develop novel formats of bsAbs with more stable structures and improved expression efficiency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Through rational design and phage display-based screening, we engineered a novel light-chain single-domain antibody (VHHL). Using modular assembly and replacement strategies, the VHHL was reconstituted into conventional immunoglobulin G (IgG)s and the resulting bsAbs were comprehensively characterized by size-exclusion high-performance liquid chromatography, biolayer interferometry binding assay, enzyme-linked immunosorbent assay, and flow cytometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A light chain engineering strategy combining complementarity-determining region 3 (CDR3)-grafting with site-directed mutagenesis of CDR1\/CDR2 was developed to generate VHHLs. Through phage screening, two mouse CD16-specific VHHL candidates with favorable binding affinities and biophysical properties were identified, and one of which was structurally resolved via X-ray crystallography (3.05\u00a0\u00c5 resolution). When incorporated into full-length IgGs, the resulting bsAbs retained high structural similarity to natural monoclonal antibodies and maintained dual antigen-binding capabilities through their respective light and heavy chains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Consequently, this study presents a novel IgG-format bsAb platform enabled by the integration of a rationally designed antigen-binding VHHL, providing a streamlined and versatile strategy for the development of multifunctional antibodies.<\/jats:p>\n                    <jats:p>Statement of Significance We developed a novel class of light-chain single-domain antibody (VHHL). By incorporating VHHL into full-length IgG, the resulting bispecific antibody (bsAb) retained the structural integrity of native IgG while preserving the independent antigen-binding activities of both the heavy and light chains, offering a simplified and flexible approach for bsAb generation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/abt\/tbaf020","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:37:21Z","timestamp":1760618241000},"page":"301-316","source":"Crossref","is-referenced-by-count":3,"title":["Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5761-3578","authenticated-orcid":false,"given":"Mingkai","family":"Wang","sequence":"first","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Department of Pulmonary and Critical Care Medicine, Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Xu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Department of Pulmonary and Critical Care Medicine, Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032 ,","place":["China"]},{"name":"Shanghai Key Laboratory of Lung Inflammation and Injury, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University , Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kong","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Department of Pulmonary and Critical Care Medicine, Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032 ,","place":["China"]},{"name":"Shanghai Engineering Research Center for Synthetic Immunology , Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Zhong","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Department of Pulmonary and Critical Care Medicine, Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yin","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Department of Pulmonary and Critical Care Medicine, Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032 ,","place":["China"]},{"name":"Shanghai Key Laboratory of Lung Inflammation and Injury, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University , Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litong","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Department of Pulmonary and Critical Care Medicine, Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlin","family":"Yang","sequence":"additional","affiliation":[{"name":"Shanghai Key Laboratory of Lung Inflammation and Injury, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University , Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9597-2843","authenticated-orcid":false,"given":"Tianlei","family":"Ying","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Department of Pulmonary and Critical Care Medicine, Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032 ,","place":["China"]},{"name":"Shanghai Engineering Research Center for Synthetic Immunology , Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Wu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Department of Pulmonary and Critical Care Medicine, Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University , Shanghai 200032 ,","place":["China"]},{"name":"Shanghai Engineering Research Center for Synthetic Immunology , Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2026050905022266700_ref1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/d41573-024-00041-3","article-title":"Top companies and drugs by sales in 2023","volume":"23","author":"Verdin","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2026050905022266700_ref2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the 'high-hanging fruit'","volume":"17","author":"Carter","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2026050905022266700_ref3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026050905022266700_ref4","doi-asserted-by":"publisher","first-page":"2321635","DOI":"10.1080\/19420862.2024.2321635","article-title":"A pivotal decade for bispecific antibodies?","volume":"16","author":"Surowka","year":"2024","journal-title":"MAbs."},{"key":"2026050905022266700_ref5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2026050905022266700_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.04.023","article-title":"Identification of human single-domain antibodies against SARS-CoV-2","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"2026050905022266700_ref7","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1016\/j.ymthe.2022.04.013","article-title":"A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors","volume":"30","author":"Wu","year":"2022","journal-title":"Mol Ther"},{"key":"2026050905022266700_ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01305-7","article-title":"Topical delivery of a human single-domain antibody targeting IL-33 to inhibit mucosal inflammation","author":"Huang","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"2026050905022266700_ref9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41401-023-01200-9","article-title":"A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity","volume":"45","author":"Zhu","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"2026050905022266700_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.03.009","article-title":"Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody","volume":"185","author":"Li","year":"2022","journal-title":"Cell."},{"key":"2026050905022266700_ref11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/protein\/gzs014","article-title":"A V(L) single-domain antibody library shows a high-propensity to yield non-aggregating binders","volume":"25","author":"Hussack","year":"2012","journal-title":"Protein Eng Des Sel"},{"key":"2026050905022266700_ref12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/s0022-2836(02)01237-8","article-title":"Biophysical properties of human antibody variable domains","volume":"325","author":"Ewert","year":"2003","journal-title":"J Mol Biol"},{"key":"2026050905022266700_ref13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1006\/jmbi.2001.4703","article-title":"Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains","volume":"310","author":"Beucken","year":"2001","journal-title":"J Mol Biol"},{"key":"2026050905022266700_ref14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jmb.2004.07.054","article-title":"Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display","volume":"342","author":"Colby","year":"2004","journal-title":"J Mol Biol"},{"key":"2026050905022266700_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2014.12.017","article-title":"Use of the amicyanin signal sequence for efficient periplasmic expression in E. coli of a human antibody light chain variable domain","volume":"108","author":"Dow","year":"2015","journal-title":"Protein Expr Purif"},{"key":"2026050905022266700_ref16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0378-1119(95)00200-p","article-title":"Domain libraries: synthetic diversity for de novo design of antibody V-regions","volume":"160","author":"S\u00f6derlind","year":"1995","journal-title":"Gene."},{"key":"2026050905022266700_ref17","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.4049\/jimmunol.150.7.2774","article-title":"Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin","volume":"150","author":"Brinkmann","year":"1993","journal-title":"J Immunol"},{"key":"2026050905022266700_ref18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jmb.2016.08.019","article-title":"abYsis: integrated antibody sequence and structure-management, analysis, and prediction","volume":"429","author":"Swindells","year":"2017","journal-title":"J Mol Biol"},{"key":"2026050905022266700_ref19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1107\/S1600576719001183","article-title":"Aquarium: an automatic data-processing and experiment information management system for biological macromolecular crystallography beamlines","volume":"52","author":"Yu","year":"2019","journal-title":"Appl Crystallogr"},{"key":"2026050905022266700_ref20","doi-asserted-by":"publisher","first-page":"118939","DOI":"10.1016\/j.ijpharm.2019.118939","article-title":"HER2-specific immunotoxins constructed based on single-domain antibodies and the improved toxin PE24X7","volume":"574","author":"Cao","year":"2020","journal-title":"Int J Pharm"},{"key":"2026050905022266700_ref21","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/eji.1830240409","article-title":"A directory of human germ-line V kappa segments reveals a strong bias in their usage","volume":"24","author":"Cox","year":"1994","journal-title":"Eur J Immunol"},{"key":"2026050905022266700_ref22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0378-1119(93)90062-8","article-title":"The immunoglobulin kappa locus-or-what has been learned from looking closely at one-tenth of a percent of the human genome","volume":"135","author":"Zachau","year":"1993","journal-title":"Gene."},{"key":"2026050905022266700_ref23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1034\/j.1600-065x.2002.19005.x","article-title":"Genetic diversity of the human immunoglobulin heavy chain VH region","volume":"190","author":"Li","year":"2002","journal-title":"Immunol Rev"},{"key":"2026050905022266700_ref24","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1002\/eji.1830231231","article-title":"Comparison of human germ-line kappa gene sequences to sequence data from the literature","volume":"23","author":"Klein","year":"1993","journal-title":"Eur J Immunol"},{"key":"2026050905022266700_ref25","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1172\/JCI117204","article-title":"Evidence that the V kappa III gene usage is nonstochastic in both adult and newborn peripheral B cells and that peripheral CD5+ adult B cells are oligoclonal","volume":"93","author":"Weber","year":"1994","journal-title":"J Clin Invest"},{"key":"2026050905022266700_ref26","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/19420862.2016.1190060","article-title":"Structural diversity in a human antibody germline library","volume":"8","author":"Teplyakov","year":"2016","journal-title":"MAbs."},{"key":"2026050905022266700_ref27","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1177\/1535370219881129","article-title":"Structure and development of single domain antibodies as modules for therapeutics and diagnostics","volume":"244","author":"Hoey","year":"2019","journal-title":"Exp Biol Med (Maywood)"},{"key":"2026050905022266700_ref28","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.molimm.2009.09.039","article-title":"A large human domain antibody library combining heavy and light chain CDR3 diversity","volume":"47","author":"Chen","year":"2010","journal-title":"Mol Immunol"},{"key":"2026050905022266700_ref29","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/emboj\/19.5.921","article-title":"Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire","volume":"19","author":"Nguyen","year":"2000","journal-title":"EMBO J"},{"key":"2026050905022266700_ref30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev.iy.09.040191.002325","article-title":"Fc receptors","volume":"9","author":"Ravetch","year":"1991","journal-title":"Annu Rev Immunol"},{"key":"2026050905022266700_ref31","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/S0021-9258(18)45867-X","article-title":"Protein L from Peptostreptococcus magnus binds to the kappa light chain variable domain","volume":"267","author":"Nilson","year":"1992","journal-title":"J Biol Chem"},{"key":"2026050905022266700_ref32","doi-asserted-by":"publisher","first-page":"19740","DOI":"10.1016\/S0021-9258(19)47174-3","article-title":"Protein L: an immunoglobulin light chain-binding bacterial protein. Characterization of binding and physicochemical properties","volume":"264","author":"Akerstr\u00f6m","year":"1989","journal-title":"J Biol Chem"},{"key":"2026050905022266700_ref33","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","article-title":"Affinity of human IgG subclasses to mouse Fc gamma receptors","volume":"9","author":"Dekkers","year":"2017","journal-title":"MAbs."},{"key":"2026050905022266700_ref34","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1016\/j.apsb.2024.03.016","article-title":"Single-domain antibodies as therapeutics for solid tumor treatment","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"2026050905022266700_ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s00251-011-0559-z","article-title":"Divergent human populations show extensive shared IGK rearrangements in peripheral blood B cells","volume":"64","author":"Jackson","year":"2012","journal-title":"Immunogenetics."},{"key":"2026050905022266700_ref36","doi-asserted-by":"publisher","first-page":"2451789","DOI":"10.1080\/19420862.2025.2451789","article-title":"Cost and supply considerations for antibody therapeutics","volume":"17","author":"Chen","year":"2025","journal-title":"MAbs."}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbaf020\/64738578\/tbaf020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/8\/4\/301\/64738578\/tbaf020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/8\/4\/301\/64738578\/tbaf020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T09:02:28Z","timestamp":1778317348000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/8\/4\/301\/8292612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10,16]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbaf020","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10]]}}}